---
title: Why collaboration between public and private investors matters
date: 2026-11-02T17:45:00+01:00
author: Linda Bak
canonical_url: "https://www.bom.nl/en/articles/waarom-samenwerking-tussen-publieke-en-private-investeerders-cruciaal-is"
section: Articles
---
#  Why collaboration between public and private investors matters 

 Background article 

 

 Public investors are playing an increasingly prominent role in funding rounds. Invest-NL, the Regional Development Agencies (ROMs) and other public investors participate in one in every three startup funding rounds. That is one of the key findings from an analysis by Mustafa Torun, Data Scientist at Invest-NL. One important insight stands out: the most promising startups emerge when public and private investors work together. Marc Jansen, Managing Director of BOM Investments, explains the value of collaboration within the investment landscape 

 

 

 

 

 

   ![Photoshop MT Marc](https://d3d5gk1jdgmand.cloudfront.net/resized/_900x600_crop_center-center_none_ns/131846/Photoshop-MT-Marc.webp)  

   

 

 

  

 

 

 

## Learn more

   ![Marc Jansen 25](https://d3d5gk1jdgmand.cloudfront.net/resized/employees/_500x500_crop_center-center_none_ns/130432/Marc-Jansen-25.webp)  

  

### Marc Jansen

Managing Director Investments and member MT

  

- [  Phone ](tel:+31652633676)
- [  Email ](mailto:mjansen@bom.nl)
- [  Chat via Teams ](https://teams.microsoft.com/l/chat/0/0?users=mjansen@bom.nl)
 
 

 

 

 

 

 

 

 

 

 

 

 

    

 

 

Mustafa Torun analysed more than 7,000 investment rounds involving startups and scale-ups between 2000 and October 2026, and shared his findings [in a column for MT/Sprout](https://mtsprout.nl/groei/invest-nl-vcs-onderzoek). Among all public investors, the Brabant Development Agency (BOM) participated in the highest number of funding rounds, followed by Oost NL and Invest-NL.

One particularly noteworthy outcome of the research is that startups and scale-ups backed by both public and private investors were twice as likely to secure a follow-on growth round as companies financed solely by private investors. “We always invest alongside a private investor, never instead of one,” says Jansen. He emphasises that strong cooperation between public and private investors is essential for startup success. “As a public investor, we become involved at a very early stage. Once a company begins to show positive results and the risks start to decrease, additional private investors are more likely to come on board.”

In the early stages, BOM’s contribution typically represents between 20 and 50 per cent of a funding round, occasionally rising to as much as 70 per cent. “After that, our share gradually decreases, but ideally we remain involved until the Series B funding round. This allows us to continue adding value where needed while maintaining our position as an investor.” In sectors characterised by high risk and long development timelines, such as deep tech, a larger public investment component is often required for longer.

## Thinking ahead

Over the years, BOM has built extensive expertise in supporting startups and works closely with entrepreneurs throughout their growth journey. “We try to look five years ahead, assessing how much capital a company is likely to need, the milestones it must achieve to attract future investment, and which investors could play a role in subsequent rounds,” Jansen explains.

This is why BOM invests heavily in building strong relationships with private investors and continuously expands its network. Every year, during the [LEVEL UP](https://levelup-event.nl/) startup event in September, a dedicated investor dinner is organised to highlight market opportunities and strengthen connections. Previous editions welcomed pension funds, while banks have been among the participants in recent years.

## Supporting startups beyond capital

In addition to investing in startups and scale-ups, BOM actively supports companies throughout their development. A range of programmes is available to entrepreneurs. One recent example is the [BioBridge programme](https://www.bom.nl/en/articles/twee-brabantse-medtech-bedrijven-verkennen-de-amerikaanse-zorgmarkt-door-acceleratieprogramma-biobridge-van-tmc), launched in partnership with Texas Medical Center to support medtech companies.

BOM’s role is to help businesses reduce risk across key areas, including product development, market validation, business model design, team development and funding strategy. “All of these aspects require attention at an early stage, and our venture developers are there to help companies address them,” says Jansen. “Many private investors do not yet provide this type of support to early-stage startups, even though laying strong foundations from the outset is critical to long-term success.” BOM’s objective is to accelerate the growth and development of innovative companies.

Jansen believes that BOM and other public investors will continue to play an important role in the years ahead. “We can dedicate significant time and attention to startups in their early stages, something the private market cannot always do. At the same time, we increasingly find it challenging to identify suitable private co-investors for early-stage opportunities. That is why more private early-stage funds must enter and remain active in the market,” he says.

For certain sectors, such as biotechnology, investors often look to the United States. BOM is therefore actively expanding its investor network both within Europe and beyond.

Ultimately, effective collaboration between public and private investors provides startups with the strongest possible support and creates greater opportunities for future growth.
